| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
DP1/prostanoid DP-receptor
BW245C's primary target is the DP1 prostanoid receptor (also known as the DP receptor). This receptor is a G-protein coupled receptor that is activated by the endogenous ligand prostaglandin D2 (PGD2). The DP1 receptor plays a crucial role in various physiological processes, including the regulation of sleep, pain perception, and inflammation. BW245C acts as a selective agonist, binding to and activating the DP1 receptor. |
|---|---|
| ln Vitro |
In Th2 cells, BW245C (0.01-1 μM) suppresses TGF-β collagen in a dose-dependent manner. Lung fibroblasts’ intracellular cAMP is likewise increased by BW245C (0.01-1 μM) [3]. The levels needed to raise transendothelial resistance and reduce FITC-dextran permeability in human venous endothelial cells are 0.1-3 μMol/L. Intracellular cAMP levels and necessary protein structure A (PKA) activity are increased by BW245C (0.3 μMol/L) [4].
In vitro, BW245C is a potent DP1 receptor agonist. It has a Ki of 0.9 nM for the inhibition of [³H]-PGD2 binding to isolated human platelet membranes. It has a reported IC50 of 2.5 nM in functional assays. It stimulates responses in embryonic bovine tracheal cells that are mediated by the DP1 receptor. Its high affinity and selectivity make it a standard tool for studying DP1 receptor function. |
| ln Vivo |
In WT mice, BW245C (0.02, 0.2, and 2.0 mg/kg) significantly increased CBF; however, what was the impact of this therapy on DP1? Not present in mice. Following a stroke, functional deficits are lessened by BW245C. After a stroke in WT mice, BW245C greatly reduced the severe decline in locomotor activity and the significant rise in neurological impairments. After receiving a BW245C injection (0.2 mg/kg) one hour post-stroke, WT showed a substantial reduction in cerebral infarction; however, at DP1? //? In mice, this therapy had no discernible effects. CBF is enhanced during and after a stroke by BW245C. When BW245C was administered, the coagulation time was significantly longer than when the vehicle-treated group was given [1]. In guinea pig esophageal epithelial cells, OVA-induced MBP acidification is not substantially increased by BW 245C (100 nM) [2].
In vivo, BW245C is used to study the physiological roles of the DP1 receptor. It has been investigated in stroke research, where activation of the DP1 receptor is thought to have neuroprotective effects. By selectively activating DP1, BW245C can mimic the effects of PGD2 and help elucidate the receptor's role in various pathophysiological conditions, including inflammation and thrombosis. |
| Enzyme Assay |
The affinity of BW245C for the DP1 receptor is typically determined using radioligand binding assays. In a cell-free protocol, membranes from cells expressing the DP1 receptor (e.g., human platelets) are incubated with a radiolabeled ligand, such as [³H]-PGD2, and varying concentrations of BW245C. The amount of bound radioligand is measured, and the Ki is calculated from the displacement curve.
|
| Cell Assay |
Isolated eosinophils (5 × 105/ml) were kept in RPMI supplemented with 1% FBS and PenStrep and stimulated with 1 μM DK‐PGD2 or BW245c for 18 h at 37°C. Cells were stained with mouse anti‐human CD193 (CCR3)–BV421 and mouse anti‐human CD49d (VLA‐4)‐PE, or the respective isotype controls. Human TruStain FcX (BioLegend) was used as Fc receptor blocking solution. Data were acquired in a BD FACS Canto II[5].
Cellular assays for BW245C involve studying its effects on DP1 receptor-mediated signaling. In a typical protocol, cells expressing the DP1 receptor (e.g., embryonic bovine tracheal cells or CHO cells) are treated with BW245C. The activation of the receptor is measured by assessing downstream signaling events, such as the accumulation of cyclic AMP (cAMP) or the mobilization of intracellular calcium. The EC50 for receptor activation is then determined. |
| Animal Protocol |
To determine if BW245C affects basal cerebral blood flow (CBF), C57BL/6 WT and DP1(-/-) mice were given a single i.p. injection of vehicle or BW245C, and CBF was recorded for 2h. To test the effect of BW245C on stroke, WT and DP1(-/-) mice were subjected to middle cerebral artery occlusion followed by a single i.p. injection of vehicle or 0.02, 0.2, or 2.0-mg/kg BW245C immediately before reperfusion. Functional and anatomical outcomes were determined at 96h. We also determined the effect of BW245C on CBF in peri-infarct and core during occlusion and reperfusion. Furthermore, we tested the effect of BW245C on bleeding time and ex vivo coagulation. BW245C treatment increased the basal CBF significantly in WT but not in DP1(-/-) mice. The BW245C treatment also significantly improved functional outcome and lowered infarction volume. The multisite CBF monitoring by laser-Doppler flowmetry shows that BW245C significantly increased the CBF in peri-infarct, with a significant inverse correlation between infarction and CBF. The significantly higher infarction volume in DP1(-/-) mice remained unchanged with BW245C treatment. Moreover, BW245C preserves hemostasis in non-stroke conditions. Combined, these data suggest that the DP1 receptor is an endogenous target that can rescue the brain following stroke by regulating CBF and hemostasis[1].
The in vivo activity of BW245C can be studied in animal models of disease. For example, in a model of stroke, BW245C may be administered to animals to assess its neuroprotective effects. The dosage and route of administration (e.g., intravenous, intraperitoneal) are optimized based on the compound's pharmacokinetic properties. The primary endpoints would be reduction in infarct size or improvement in neurological function. |
| ADME/Pharmacokinetics |
BW245C is a small molecule with a molecular weight of 394.51 and a molecular formula of C₂₂H₃₄N₂O₄. It is typically supplied as a powder for research use. Its solubility is enhanced in DMSO. As a research chemical, detailed pharmacokinetic data are not typically reported, as its primary use is in in vitro and ex vivo studies. However, its properties are well-suited for use in biological assays.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BW245C is not extensively documented, as it is a research tool rather than a therapeutic candidate. Standard safety precautions should be taken when handling the compound. At concentrations used in in vitro assays (typically in the nanomolar to micromolar range), it is not considered highly toxic. For in vivo studies, the dose would be carefully selected to avoid systemic toxicity.
|
| References |
[1]. Ahmad AS, et al. PGD2 DP1 receptor stimulation following stroke ameliorates cerebral blood flow and outcomes. Neuroscience. 2014 Oct 24;279:260-8.
[2]. Zhang S, et al. Prostaglandin D2 receptor D-type prostanoid receptor 2 mediates eosinophil trafficking into the esophagus. Dis Esophagus. 2014 Aug;27(6):601-6. [3]. Ayabe S, et al. Prostaglandin D2 inhibits collagen secretion from lung fibroblasts by activating the DP receptor. J Pharmacol Sci. 2013;121(4):312-7. Epub 2013 Mar 29. [4]. Kobayashi K, et al. Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway. Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):565-71. [5]. DP1 receptor signaling prevents the onset of intrinsic apoptosis in eosinophils and functions as a transcriptional modulator. J Leukoc Biol. 2018 Jul; 104(1): 159–171. |
| Additional Infomation |
7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-yl]heptanoic acid is an imidazolidine-2,4-dione with the structure 7-(2,5-dioxoimidazolidine-4-yl)heptanoic acid, wherein the 3-position of the imidazoline ring is substituted with a 3-(3-cyclohexyl-3-hydroxypropyl) group. It is an imidazolidine-2,4-dione, a secondary alcohol, and a monocarboxylic acid.
BW245C is a selective agonist for the DP1 prostanoid receptor. It is a prostaglandin analog used as a research tool to study the physiological and pathophysiological roles of the DP1 receptor. It is widely utilized in stroke and disease research. It is not an approved drug and has no clinical applications, but it is a valuable compound for investigating prostaglandin signaling pathways. |
| Molecular Formula |
C19H32N2O5
|
|---|---|
| Molecular Weight |
368.474
|
| Exact Mass |
368.231
|
| Elemental Analysis |
C, 61.93; H, 8.75; N, 7.60; O, 21.71
|
| CAS # |
72814-32-5
|
| Related CAS # |
(8-epi)-BW 245C;65705-83-1
|
| PubChem CID |
119304
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.521
|
| LogP |
2.12
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
26
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C([H])(C([H])([H])C([H])([H])N1C(N([H])C(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(=O)O[H])=O)=O)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]
|
| InChi Key |
ZIDQIOZJEJFMOH-JKSUJKDBSA-N
|
| InChi Code |
InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16+/m0/s1
|
| Chemical Name |
7-[(4S)-3-[(3R)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxoimidazolidin-4-yl]heptanoic acid
|
| Synonyms |
BW-245C; BW 245C; BW 245C; 72814-32-5; BW245C; 72880-75-2; (R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid; 5B26TJM1L8; (3R,4S)-BW 245C; 4-Imidazolidineheptanoic acid, 3-((3R)-3-cyclohexyl-3-hydroxypropyl)-2,5-dioxo-, (4S)-rel-;
BW245C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~135.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL | |
| 5 mM | 0.5428 mL | 2.7139 mL | 5.4279 mL | |
| 10 mM | 0.2714 mL | 1.3570 mL | 2.7139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
